Biotechnology
Scinai Immunotherapeutics Ltd is a biopharmaceutical company focused on developing, manufacturing and commercializing products for the prevention and treatment of infectious diseases and other illnesses. It has executed eight clinical trials in seven countries, around 12,400 participants in the Phase 3 trial of its vaccine candidate and has built a GMP biologics manufacturing facility for biopharmaceutical products. The company is aiming to develop a pipeline of diversified and commercially viable products and platforms beginning with a nanosized antibody (NanoAb) pipeline.

$2.9M

Market Cap • 12/26/2024

2003

(21 years)
Founded

2015

(9 years ago)
IPO

NASDAQ

Listing Exchange
Flag of IL

Jerusalem

Headquarters